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ABSTRACT 
A number of human disorders, including  Cockayne syndrome, UV-sensitive syndrome, 
xeroderma pigmentosum and trichothiodystrophy, result from the mutation of genes 
encoding molecules important for nucleotide excision repair. Here, we describe a novel 
syndrome in which the cardinal clinical features include postnatal growth retardation, 
hearing loss, premature aging, telangiectasia, neurological signs and photosensitivity, 
resulting from a homozygous missense (p.Ser228Ile) sequence alteration of the 
proliferating cell nuclear antigen (PCNA). PCNA is a highly conserved sliding clamp 
protein essential for DNA replication and repair. Due to this fundamental role, mutations 
in PCNA that profoundly impair protein function would be incompatible with life. 
Interestingly, while the p.Ser228Ile alteration appears to have no effect on protein levels 
or DNA replication, patient cells exhibit significant abnormalities in response to UV 
irradiation displaying substantial reductions in both UV survival and RNA synthesis 
recovery. The p.Ser228Ile change also profoundly alters PCNA’s interaction with Flap 
endonuclease 1 and DNA Ligase 1, DNA metabolism enzymes. Taken together our 
findings detail the first mutation of PCNA in humans, associated with a unique 
neurodegenerative disease displaying clinical and molecular features common to other 
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INTRODUCTION 
Maintenance of genomic integrity is fundamentally important for normal cell division and 
basic cellular biological processes.  The molecular characterization of human DNA 
damage sensitivity disorders such as ataxia telangiectasia (AT), xeroderma 
pigmentosum (XP) and Cockayne syndrome (CS) has provided unique insight into the 
cellular mechanisms required for DNA damage tolerance and repair, and their 
importance for human health. The key features of such syndromes include 
predisposition to premature aging, malignancy, neurodegeneration, immunodeficiency, 
photosensitivity and growth insufficiency (1-4). The process of nucleotide excision repair 
(NER) comprises two DNA repair pathways that are crucial for the removal of bulky 
lesions in DNA including photoproducts resulting from exposure to ultraviolet (UV) light. 
Transcription-coupled nucleotide excision repair (TC-NER) rapidly undertakes 
preferential repair of DNA lesions on actively transcribed DNA strands and is deficient in 
CS and UV-sensitive syndrome (5). Global genome repair (GG-NER), removes 
photoproducts more slowly from across the genome and is deficient in XP and 
trichothiodystrophy (6). After DNA damage is detected, both NER processes involve the 
excision of about 30 nucleotides encompassing the damaged DNA followed by repair 
synthesis of new DNA to replace the damaged section. Repair synthesis is absolutely 
dependent on the DNA polymerase accessory protein PCNA (7). This protein’s major 
cellular role is to recruit and retain the replicative DNA polymerases at the sites of DNA 
synthesis during DNA replication. It forms a homotrimeric ring encircling and freely 
sliding along the DNA helix. PCNA interacts with a large number of accessory proteins 
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and acts as a protein recruitment platform to coordinate the multiple enzymatic activities 
that are required for DNA replication and repair (8).  
In the current study, four affected individuals aged between 11 and 31 years affected by 
a novel syndrome, were identified from a single extended pedigree comprising two 
kindreds within the Ohio Amish community (Figure 1). The principal features include 
neurodegeneration, postnatal growth retardation, prelingual sensorineural hearing loss, 
premature aging, ocular and cutaneous telangiectasia, learning difficulties, photophobia 
and photosensitivity with evidence of a predisposition to sun-induced malignancy. 
Phenotypic similarities with XP, CS and AT were noted (Table 1). All four affected 
individuals displayed short stature ranging from -3.8 to -5.2 SDS, with an absence of 
pubertal growth spurt in the two eldest individuals. Neurodegeneration was a consistent 
feature, characterized by progressive gait instability, muscle weakness, foot deformity, 
difficulties with speech and swallowing, learning difficulties and cognitive decline with 
advancing age. Prelingual onset of moderate to profound (worse at high frequency) 
sensorineural hearing loss was universal, a feature not commonly associated with the 
recognized DNA repair defects, and there was clear evidence of progression in VI:9. 
Muscle weakness was progressive (VI:6 has been wheelchair bound since the age of 
16 years with contractures in all 4 limbs). Speech was unclear from onset and 
deteriorated with age (VI:6 currently has no speech and communicates with basic 
gestures). Progressive difficulty with swallowing solids/drooling was present in 3/4 
affected subjects. Neuroimaging was only available in one case (VI:7). Magnetic 
resonance imaging of the brain aged eight years demonstrated cerebellar atrophy 
involving the cerebellar vermis and hemispheres.  Inner ear abnormalities included 
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bilateral mild labyrinthine dysplasia with mildly dilated vestibules. All exhibited 
photophobia and photosensitivity, with evidence of premalignant changes in VI:11 
(basal cell carcinoma in situ).  All have several cutaneous telangiectasias and 3/4 have 
conjunctival telangiectasia.  
Assuming that a founder mutation was responsible for the condition, we used a 
combination of autozygosity mapping and linkage analysis in order to study this novel 
syndrome and identify the underlying molecular cause. 
 
RESULTS 
A genome-wide SNP microarray scan of DNA from affected individuals and parents was 
undertaken. Inspection of resultant genotypes identified a single notable region of 
homozygosity of ~2.72Mb on chromosome 20p13, shared solely by the three affected 
females. In the affected male, a de novo telomeric recombination event reduced this 
region to ~0.77Mb, delimited by markers rs404678 and rs6139841, 
NC_000020.10:g.5024237-5792923 (Figure 1), likely to correspond to the disease locus 
(LODMAX 6.4). Microsatellite marker analysis confirmed autozygosity across this region 
(data not shown). We sequenced all six protein coding genes in the region (PCNA, 
CDS2, PROKR2, GPCPD1, C20orf30 and C20orf196), revealing only a single 
potentially pathogenic sequence variant (NM_002592.2 c.683G>T) in exon 6 of PCNA. 
This variant, which cosegregated with the disease phenotype and was verified in the 
RNA transcript obtained from whole blood of an affected individual, is predicted to result 
in a substitution of a stringently conserved serine at position 228 for isoleucine 
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(p.Ser228Ile) (Supplemental Figure S1). The variant was not detected in 360 control 
chromosomes of European ancestry and only two heterozygous carriers were detected 
in the analysis of 310 Ohio Amish control chromosomes, which is not unexpected in this 
endogamous community. Only a single heterozygous carrier of European origin was 
identified in online sequencing project databases (1000 genomes project and the 
Exome Variant Server, ESP6500SI release). This single mutation carrier in 7775 non-
Amish individuals genotyped corresponds to a homozygous PCNA c.683T allele 
incidence in the region of ~1:241 million. We also subjected a single affected individual 
to whole exome sequence analysis (Otogenetics Corporation) to exclude other possible 
genetic causes. As expected this confirmed the presence of the PCNA variant but 
identified no other known or possible pathogenic variants elsewhere after excluding 
variants not compatible with recessive inheritance or cosegregating with the disease 
phenotype. Further conclusive support for the exclusion of a diagnosis of AT and “AT-
like” disorders was provided by our findings including normal chromosomes (untreated 
or γ-ray-induced, patient VI:11), AFP levels, immunoglobulin patterns (VI:7 and 9), ATM 
and associated protein and kinase activity levels (patients VI:6 and 11) (Supplemental 
Figures S2, S3) in affected subjects. 
PCNA is an essential DNA replication accessory protein, highly conserved throughout 
evolution. It plays a central role at the replication fork, recruiting and retaining many of 
the enzymes required for DNA replication (8). Due to its fundamentally important cellular 
role, mutations that significantly affect PCNA protein function would be predicted to 
result in embryonic lethality. However the survival of PCNALys164Arg/Lys164Arg knock-in 
mice, generated to determine the role of PCNA lysine 164 modifications in somatic 
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hypermutation, demonstrates that certain hypomorphic mutations of PCNA can be 
tolerated in mammals (9). However, no inherited human disorder arising from PCNA 
mutation has been described previously. 
We therefore investigated the functional consequences of the p.Ser228Ile PCNA 
alteration. Primary fibroblasts were established from three affected individuals, VI:11, 
VI:9 and VI:7 (P1, P2, P3), two heterozygous carriers (Het1, Het2) and wild type 
controls (WT). EBV transformed lymphoblastoid cells were established from two 
affected individuals VI:11 and VI:6 (L5, L6), two carriers (L8, L10) and two Amish wild 
type controls (L7, L9). PCNA protein levels are unaltered in cells from affected 
individuals (Supplemental Figure S2). In order to assess the influence of the p.Ser228Ile 
alteration on DNA replication we incubated primary fibroblasts (at < passage 10) with 
BrdU (5-Bromo-2´-Deoxyuridine) for 30 minutes and analyzed the incorporation and 
DNA content by FACS (Figure 2A). No significant differences were observed when 
comparing the fibroblasts from affected individuals with wild type or heterozygote 
controls. During S phase, PCNA is recruited to so called “DNA replication factories”, 
which are the sites of nucleotide incorporation and are visible as foci in the nuclei of 
replicating cells. Immunofluorescence analysis of endogenous PCNA in fibroblasts from 
affected individuals revealed no abnormalities in these foci (Figure 2B). In addition, no 
difference in replication fork rate was detected during unperturbed S phase using DNA 
fiber analysis (Figure 2C). Taken together, these data lead us to conclude that the 
Ser228Ile variant does not dramatically interfere with the major replicative function of 
PCNA and that bulk DNA replication is not grossly perturbed. 
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Given that repair synthesis and downstream events of NER are absolutely dependent 
on PCNA (7), the reported photosensitivity in p.Ser228Ile homozygotes prompted us to 
examine the effect of the p.Ser228Ile substitution on cellular sensitivity to UV. Both 
fibroblast and lymphoblastoid cells from affected individuals are more sensitive to UV 
irradiation than cells with wild-type PCNA (Figure 3A, 3B), suggesting that the mutation 
specifically impairs the function of PCNA in DNA repair. To investigate this further, we 
evaluated GG-NER in primary fibroblast cell lines, measured by the unscheduled DNA 
synthesis (UDS) assay (10). In cells from affected individuals UDS was reproducibly 
reduced to approximately 50-60% of normal values (Figure 3C). RNA synthesis 
recovery levels following UV radiation (RRS) were used as a marker of TC-NER (11). 
RRS was significantly decreased, to approximately 30-50% of normal in cells from 
affected individuals (Figure 3D, Supplemental Figure S4). The deficiency approaches 
that of CS cells, known to be defective in TC-NER. Importantly, ectopic expression of 
wild-type PCNA fully rescued the RRS deficiency (Figure 3E) (12), whereas it had only 
a minor effect on RRS in normal fibroblasts (Supplemental Figure S5), demonstrating 
that the deficient UV responses are caused by the p.Ser228Ile sequence alteration. 
Although the two assays for UDS and RRS are, by their very nature, different from each 
other and are semi-quantitative, these results suggest that a subtle alteration in PCNA 
structure resulting from the p.Ser228Ile substitution is sufficient to specifically disrupt its 
role in NER and this appears to have a more significant effect on TC-NER.  
Serine 228 lies near the external face of PCNA and the mutation is therefore unlikely to 
affect its interaction with DNA (Figure 4A). This residue is also distant from the regions 
of PCNA that mediate the formation of the trimeric ring structure (13). Consistent with 
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this, no differences in trimer formation or stability between recombinant PCNAWT and 
PCNASer228Ile proteins were detected using gel filtration or glycerol gradient 
sedimentation (data not shown), and the amount of chromatin-associated PCNA 
(resistant to detergent extraction) was similar in wild-type and p.Ser228Ile homozygous 
cells. Interestingly however, the altered residue is close to the inter-domain connecting 
loop (IDCL) region mediating the interaction of PCNA with many of its protein partners. 
PCNA partner proteins, including DNA polymerase delta (PolD), DNA Ligase 1 (Lig1) 
and Flap endonuclease 1 (Fen1), often contain a PCNA interacting protein (PIP) box, a 
sequence motif which mediates the IDCL-interaction (14). In published crystal structures 
serine 228 does not directly contact the PIP box-containing peptide (13, 15), although 
its close proximity to the interaction region may generate subtle positional alterations 
within this crucial domain, with functional consequences. 
To determine whether specific protein interactions are perturbed by the p.Ser228Ile 
alteration, we performed a SILAC (stable isotope labeling by amino acids in culture) 
affinity purification assay. Extracts were made from HeLa cells grown in either normal 
medium, or SILAC medium containing “heavy” amino acids: [13C6/
15N2] lysine and 
[13C6/
15N4] arginine. These extracts were individually exposed to affinity columns 
comprising recombinant PCNA, either wild-type (WT) or PCNASer228Ile. Proteins that 
bound to each column were eluted, the eluates combined, and the relative binding to 
each column was determined by mass spectrometry. This identified clear perturbations 
in the interaction of PCNASer228Ile with a limited number of interacting partners, most 
strikingly with Fen1 and Lig1 (Figure 4B, Supplemental Table S1). This experiment 
revealed relatively increased amounts of Fen1 and Lig1 in the 500mM eluates from the 
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PCNASer228Ile column, when compared to the WT column. To investigate this unexpected 
finding further, we analyzed the salt resistance of the PCNA-Fen1 interaction. HeLa 
nuclear extract was incubated with His-PCNA (WT or p.Ser228Ile) beads, which were 
then washed with increasing NaCl up to 500mM. The material eluted at 1M NaCl and 
that which was retained on the beads was subsequently analyzed by western blot for 
Fen1 (Figure 4C). This clearly demonstrates that the interaction between Fen1 and WT 
PCNA is much more resistant to high salt concentrations than the interaction between 
Fen1 and PCNAp.Ser228Ile. This leads us to conclude that in the SILAC experiments 
(Figure 4B), Fen1 remained bound to the WT-PCNA column during the elution with 
500mM NaCl, resulting in a dramatic reduction of this protein in the WT eluate. This 
conclusion, that the p.Ser228Ile change impairs the ability of PCNA to bind Fen1, was 
further validated by our subsequent immunoprecipitation and GST pull down 
experiments (described below). 
We next assessed the effects of the p.Ser228Ile PCNA alteration in a more 
physiological setting by immunoprecipitation from lymphoblastoid cell extracts. While an 
interaction between Fen1 and PCNA was clearly demonstrated in controls, an 
intermediate level of interaction was detected in heterozygote cell lines and the 
interaction was barely detectable in cells homozygous for the Ser228Ile PCNA alteration 
(Figure 4D). These data provide unambiguous confirmation that interaction of Fen1 with 
PCNA is dramatically reduced by the p.Ser228Ile mutation. 
We have been unable to identify a commercially available antibody against Lig1 that is 
effective for immunoprecipitation from our lymphoblastoid extracts.  Thus, in order to 
further investigate the effect of the Ser228Ile PCNA alteration on the interaction 
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between PCNA and Lig1 we utilized an in vitro approach (16). Lysates were prepared 
from E.coli expressing a fusion protein comprising GST and the PIP box motif of either 
Fen1 or Lig1. These were then mixed with lysate containing either wild type or 
p.Ser228Ile PCNA and glutathione beads were added, the proteins that associated with 
the beads were subsequently analyzed by SDS-PAGE. This assay recapitulates the 
defective interaction between PCNASer228Ile and Fen1 (Figure 4E), and most significantly 
shows that the Ser228Ile protein also has a reduced affinity for the PIP box of Lig1 
(Figure 4F, left panel).  
Given that Fen1 and Lig1 are both implicated in the NER pathways (17, 18), it is 
plausible that the cellular NER defects observed in cells from affected individuals result 
from the compromised interactions of these proteins with p.Ser288Ile PCNA. It also 
seemed likely that the Ser228Ile alteration would perturb the PCNA interaction with 
other PIP box containing partners, and that this may contribute to the cellular 
phenotypes observed.  One clear candidate known both to be required for NER and to 
bind PCNA through a PIP box interaction is XPG (16). We did not detect peptides 
derived from XPG in our SILAC assay, which by its nature will only detect proteins 
which are relatively abundant and interactions which are relatively strong. In the 
absence of an XPG antibody suitable for immunoprecipitation of endogenous XPG, the 
GST assay was again used to assess the binding of WT PCNA and p.Ser228Ile to the 
PIP box of XPG. Crucially, although less WT PCNA was bound to the XPG PIP box 
when compared to its binding to the Fen1 PIP box, the pSer228Ile PCNA displayed no 
detectable interaction with the XPG PIP box (Figure 4F, right panel). Thus, it seems 
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reasonable to suggest that a defective interaction with XPG is also likely to contribute to 
the NER phenotype seen in cells homozygous for p.Ser228Ile PCNA. 
 
DISCUSSION 
The genetic and cellular data described here implicate PCNA in a new distinct 
neurodegenerative DNA repair disorder displaying some features in common with other 
conditions associated with deficient DNA metabolism including CS, XP and AT. The 
most notable similarities between CS, the neurological form of XP and the individuals 
with PCNA mutation described here include growth abnormalities, premature ageing, 
cognitive decline, photosensitivity and photophobia. The presence of a basal cell 
carcinoma in situ in one affected individual (VI:11) likely indicates a predisposition to 
sun-induced malignancy in individuals homozygous for PCNA p.Ser228Ile mutation, and 
further clinical overlap with XP. However the phenotype associated with p.Ser228Ile 
mutation of PCNA appears in general to be milder than that seen with either typical CS 
or XP, most noticeably the rate of premature ageing seems to be slower, with none of 
the ophthalmic manifestations associated with CS reported and the effects of UV 
sensitivity less significant. Interestingly, although hearing loss is found in CS and some 
XP patients, the age of onset is typically later (1, 4). Thus, prelingual sensorineural 
hearing loss may, in association with the other clinical features described, be a helpful 
diagnostic feature in patients with this condition. The ocular and cutaneous 
telangiectasia seen in patients with the PCNA p.Ser228Ile mutation are reminiscent of 
those seen in AT, as is the pattern and progression of neurological abnormalities, 
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although as with CS and XP, PCNA p.Ser228Ile homozygotes generally appear to be 
less severely affected than typical AT patients. As with CS and XP, there are also 
striking differences between the phenotype associated with PCNA p.Ser228Ile and AT, 
including an absence of both the immunodeficiency and oculomotor apraxia commonly 
seen in AT affected individuals. 
Complete disruption of PCNA in flies or yeast is lethal (19, 20) an expected finding 
given its fundamental involvement in DNA replication. Until now, no pathological 
mutations in the PCNA gene have been reported in human populations. In other species 
however, some mutations of PCNA are compatible with life. For example, point 
mutations have been produced in the S. cerevisiae PCNA gene (POL30) that result in a 
wide variety of phenotypes, including DNA damage sensitivity, alterations in mutation 
rate and epigenetic silencing defects (21). Similar phenotypes are seen in the various 
reported mutations in Drosophila PCNA (mus209) (19). The only previously reported 
pathological mutation of PCNA in mammalian systems is a targeted missense mutation 
of lysine 164 to arginine (PCNAp.Lys164Arg) in mice, generated to assess the role of 
ubiquitination at this residue in somatic hypermutation in the immune system (9). 
Ubiquitination of PCNA at lysine 164 is essential for translesion synthesis, a DNA 
damage tolerance process (22). Mice homozygous for PCNAp.Lys164Arg are viable, but 
infertile and have an altered mutation spectrum of hypermutated immunoglobulin genes 
(9, 23). Thus a subtle mutation of PCNA that impinges upon a specific function can lead 
to characteristic loss of function effects on DNA metabolism.   
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Consistent with this, our assays suggest that the PCNA p.Ser228Ile mutation described 
here is hypomorphic in nature. We did not detect any gross abnormalities of DNA 
replication associated with this mutation. Instead, we showed that the mutation has 
distinctive consequences for the cellular responses to UV, affecting both GG-NER and 
TC-NER. The effects on RRS seen in CS cell lines, and on UDS in XP cell lines, are 
typically more dramatic than we observed in homozygous PCNA p.Ser228Ile cells. This 
may in part explain why the phenotypic manifestations associated with these cellular 
abnormalities are not as profound in the individuals described here when compared to 
those seen in CS and XP. 
Our studies define particular defective interactions of p.Ser228Ile PCNA which, together 
with others not yet recognized, are likely to be responsible for the specific alterations in 
cellular activities we observed. The altered protein interaction capability of the 
pSer228Ile PCNA is also likely to account for the clinical manifestations of this 
syndrome. Complete abrogation of the PCNA-Fen1 interaction, mediated by a 
homozygous mutation of the Fen1 PIP box, is lethal in mice (24). Hence, it seems likely 
that while the p.Ser228Ile alteration dramatically reduces the association between 
PCNA and Fen1 in cell extracts, it is unlikely to completely abrogate their functional 
partnership. Consistent with this, both our SILAC and interaction assays using 
recombinant proteins show that the p.Ser228Ile protein remains capable of interacting 
with Fen1, although with significantly altered affinity. We cannot conclude from our 
assays whether the defective interactions with XPG, Fen1 and Lig1 are solely 
responsible for the observed effects on NER, although it is important to note that all 
these proteins are reported to be involved in this repair pathway (6, 17, 18). Thus, the 
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perturbation of their interactions with PCNA could well be a major contributor to this 
abnormal cellular phenotype.  
Mutations in XPG are rare, and can be divided into two categories: mis-sense mutations 
in the nuclease domains abrogate NER but result in relatively mild XP phenotypes, 
while truncating mutations cause a very severe XP/CS complex disorder (25, 26). The 
xpg-/- mouse is barely viable (27). These varying phenotypes are thought to result 
because, in addition to its function in NER, XPG is involved in other processes (26). In 
particular, it associates with the transcription factor TFIIH, and RNA polymerase II, and 
has a role in transcription (25, 28, 29). It is the disruption of these other functions of 
XPG that is thought to be responsible for the more severe features of truncation 
mutations. As an example, patient XPCS1RO had severe early-onset CS and died aged 
7 months. He was homozygous for a frame-shift mutation at codon 926 of XPG. This 
mutation leaves the nuclease domains intact, but truncates the protein before the PIP-
box and nuclear localization signal (30). Thus, the C-terminal region of XPG, including 
the motif responsible for interacting with PCNA, is very important for XPG function. 
These observations lead us to suggest that perturbation of PCNA’s interaction with XPG 
may contribute to the neurological features associated with PCNA p.Ser228Ile.  
In contrast to the homozygous state, mice heterozygous for the Fen1 PIP box mutant 
are viable, though they show predisposition to malignancy (31). Although specific PIP 
box mutations of Lig1 have not been generated in mammals, loss of function mutations 
in LIG1 have been reported in a single individual and result in a complex human 
phenotype comprising growth restriction, immunodeficiency and photosensitivity (32), 
features reminiscent of those seen in p.Ser228Ile homozygotes. It is possible that Lig1 
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deficiency and PCNA p.Ser228Ile homozygosity together represent a group of 
conditions that are the result of disruption to multiple different DNA repair pathways. In 
addition, while the observed cellular defects correlate with the CS and XP like features 
of the syndrome, the clinical overlap with AT will require further investigation.  
As well as being crucial to the maintenance of genomic integrity and prevention of 
neoplastic changes, DNA repair is known to be fundamentally important both during the 
rapid proliferative phase characteristic of early neurogenesis, and in the prevention of 
early cell death. The affected individuals with PCNA mutation described in this study 
display signs of neurodegeneration, a recognized feature of CS, AT as well as 
neurological forms of XP, although the pathological patterns seen in each are distinct. 
More detailed investigation of the altered biological processes resulting from the 
p.Ser228Ile PCNA alteration will thus provide invaluable insight into the biological basis 
of this novel human disorder, as well as the neurodegenerative disease mechanism(s) 
involved in DNA damage tolerance and repair disorders. Further, while mutations 
resulting in complete loss of function of PCNA in humans may be incompatible with life, 
it remains an intriguing possibility that additional sequence variants in this gene, 
affecting other distinct aspects of PCNA function, might be viable and result in a 
phenotype more or indeed less severe than that associated with the p.Ser228Ile 
alteration described here. 
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METHODS 
Genetic studies. SNP genotyping was carried out using Illumina Human CytoSNP-
12v2.1 330K arrays. Multipoint linkage analysis was performed with MERLIN (33) under 
a model of autosomal recessive inheritance with full penetrance, assuming a disease 
allele frequency of 0.0001. Unique primers for sequencing and microsatellite analysis 
(Sigma-Aldrich) were designed using online software Primer3web (34) using sequences 
from the UCSC Genome Browser. RT-PCR was carried out using Clontech™ One Step 
RT-PCR Kit following manufacturer’s instructions, and bidirectional dideoxy DNA 
sequencing performed on an ABI3130 XLA capillary sequencer (Applied Biosystems) 
with analysis using Finch TV 1.4.0 (Geospiza Inc.) and Gene Tool 1.0.0.1 (Bio Tools 
Inc). Whole exome sequencing was performed by the Otogenetics Corporation using 
the SureSelect Human All Exon V4 (Agilent Technologies) exome enrichment kit on an 
Illumina HiSeq2000. The exome sequencing produced 31,783,299 mapped reads, 
corresponding to 93% of targeted sequences covered sufficiently for variant calling 
(>10X coverage, mean depth 45X). 
Cell studies. Cells were cultured in DMEM/RPMI (Sigma Aldrich) with 15% fetal bovine 
serum (FCS - hyclone), 2mM Glutamine (Invitrogen) and 1% penicillin and streptomycin. 
UV sensitivity of lymphoblastoid cells was determined by irradiating cells in PBS (1x106 
viable cells in 1ml) with UVC (254nm, 1Jm-2sec-1), adding 4ml growth medium and 
counting viable cells using trypan blue exclusion after a 72 hour recovery period. UDS, 
RNA synthesis, fibroblast survival assays and lentiviral mediated complementation were 
performed as described previously (10-12, 35-37). 
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Protein interaction analyses. Recombinant PCNA (WT and p.Ser228Ile) were 
produced with a His-tag from pET28b in E.coli BL21 codonplus (Novagen), and purified 
on Ni-NTA sepharose (Qiagen). Affinity columns were made by covalently linking these 
proteins to NHS-activated sepharose (Pierce). For SILAC analysis HeLa cells were 
grown in SILAC DMEM (Gibco) supplemented with 10% dialyzed FBS, 2mM CaCl2, 
1mM MgSO4, 52mg/l L-leucine and 100mg/l L-lysine and L-arginine (for “heavy” extracts 
[13C6/
15N2] lysine and [
13C6/
15N4] arginine (CKgas) were substituted). Extracts were 
made by lysing cells in a low salt buffer containing benzonase (Merck), then adjusting to 
150mM NaCl. All protein interaction assays were performed in interaction buffer (25mM 
Tris pH 7.5, 25mm NaCl, 10% glycerol, 0.01% Igepal, 1mM PMSF). Proteins eluted 
from PCNA affinity columns with 500 mM NaCl were combined before 10-fraction mass 
spectrometric (MS-MS) analysis (MS Bioworks). Data was analyzed, and H:L ratios 
determined using MaxQuant software. To further analyze the stability of PCNA 
interactions, recombinant PCNAs were added to HeLa nuclear extract (4C), complexes 
were isolated on Ni-NTA agarose, and sequentially washed and eluted with increasing 
[NaCl]. For immunoprecipitations, protein extracts were made from lymphoblastoid cells 
as above. Fen1 protein was precipitated using an anti-Fen1 rabbit antibody 
(EPR4459(2), GeneTex) and ProteinA/G dynabeads (Invitrogen). Proteins in the 
extracts and precipitates were analyzed by western blot with anti-PCNA (PC10, Abcam) 
or anti-Fen1 (4E7, GeneTex). GST fusion protein association studies were performed 
as in (16), using lysates from E.coli harboring pET30a as a control, or PCNA (WT or 
p.Ser228Ile) expressed from pET30a. These were mixed, in a buffer containing 100mM 
KH2PO4/K2HPO4, with lysates from E. coli expressing glutathione S transferase (GST) 
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or fusion proteins comprising GST and the PIP boxes of Fen1 (amino acids 328-355), 
XPG (amino acids 981-1009) or Lig1 (amino acids 1 – 21 with an 8 amino acid glycine-
serine spacer to maintain an equal distance between the GST and the PIP box in all 
cases). 
Western Blotting. Exponentially growing primary human fibroblast cells were lysed on 
ice in 50mM Tris-HCl pH 7.5, 150mM NaCl, 200µM EDTA, 1% NP-40. Extracts were 
clarified by centrifugation at 10,000g for 10 min at 4°C and extracts fractionated by 
SDS-PAGE. Proteins were transferred to Protran nitrocellulose (Whatman) and 
immunoblotted with anti-PCNA (PC10, Abcam) or anti-Fen1 (4E7, GeneTex). The ATM 
kinase activity assay and western blotting of ATM and associated proteins in 
lymphoblastoid cells was carried out as described in (38). 
FACS analysis of cell cycle position. Primary fibroblasts were incubated with 10 µM 
BrdU for 30 minutes then trypsinized and fixed by the addition of methanol to 70%. After 
storage at -20 °C cells were treated with 0.2 mg/ml pepsin in 2M HCl for 20 minutes, 
then incubated in 0.5% BSA in PBS with 0.5% tween 20 and a 1/50 dilution of anti-BrdU 
antibody (Becton Dickinson) for 1 hour. After washing in 0.5% BSA, incubation with 
1/100 anti-mouse secondary antibody coupled to Alexa Fluor 488 (Molecular Probes) 
was for 30 minutes, followed by washing and resuspension in PBS with 0.5 mg/ml 
RNaseA for 15 minutes. Propidium iodide was added (10 µg/ml) just before analysis on 
a CyAn™ ADP Analyzer (Beckman Coulter, Inc.). 
Immunofluorescence. EdU staining was carried out using the Click-iT EdU Alexa Fluor 
555 Imaging Kit (Invitrogen). Cells were seeded onto glass coverslips so as to be 
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subconfluent at the time of fixation. At least 24 h after plating EdU was added to the 
culture medium to a final concentration of 20 µM and cells returned to 37°C for 10 min. 
Soluble proteins were extracted by rinsing once in PBS, once in CSK buffer (100mM 
NaCl, 300mM sucrose, 10mM PIPES pH 7.0, 3mM MgCl2), and then soaking in CSK 
plus 0.2% Triton X-100 for 5 min on ice. After a further wash in CSK cells were fixed 
(ice-cold methanol for 20 min at -20°C), washed twice more in PBS, and then blocked 
(5% w/v bovine serum albumin (BSA) in PBST) for 30 min at room temperature. EdU 
staining was carried out according to manufacturer’s instructions. Coverslips were then 
incubated for 1 h at room temperature in blocking buffer containing anti-PCNA 
monoclonal antibody (PC-10) diluted 1:1000, followed by 3 washes in PBST and 
incubation in Alexa Fluor 488 goat anti-rabbit immunoglobulin G (Invitrogen) diluted 
1:1000 in blocking buffer for 45 min. Cells were rinsed a further 3 times in PBST, and 
coverslips mounted in Aqua-Poly/Mount (Polysciences) containing DAPI at a final 
concentration of 1.5µg/ml. Slides were visualized using a Leica SP5 confocal 
microscope. 
DNA fiber analysis. Immunolabelling of DNA fiber spreads was carried out as 
described in (39), with minor modifications. Cells were incubated in IdU and CldU at a 
final concentration of 100 µM for 20 min each, and all antibody incubations were for 2 h 
at room temperature. Fibers were mounted in ProLong mounting medium (Invitrogen). 
Study approval. The present studies in humans were reviewed and approved by The 
Institutional Review Board of the Office for the Responsible Conduct of Research, 
University of Arizona, Tucson, Arizona (reference 10-0050-01).  
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 All tissue samples were taken with informed consent in accordance with all ethical 
standards and protocols.  Subjects or their guardians provided informed consent prior to 
their participation in the study. Written informed consent was obtained to publish the 
photographs of affected individuals. 
Statistics overview. In graphical representations of experimental data, error bars on 
graphs represent the standard error of the mean (SEM) or range of the plotted mean of 
at least 2 independent experiments, as indicated in the figure legends. 
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Figure 1: Family pedigree showing PCNA c.683G>T genotype data, and images of 
affected individuals. (A) A simplified pedigree of the extended Amish family 
investigated, with pictorial representation of genotypes across ~6Mb of chromosome 20 
encompassing the disease locus (2.7Mb autozygous section in affected females 
indicated by blue hashed box, and the common 0.78Mb region indicated by red box). All 
affected individuals were subsequently shown to be homozygous for the PCNA 
(NM_002592.2 c.683G>T) variant (indicated). Parental samples were heterozygous and 
unaffected siblings were either wild type or heterozygous carriers. The genotype is 
shown in red under individuals in generations V and VI, with (+) denoting mutant and (-) 
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wild type.  (B) Electropherograms showing the DNA sequence at the position of the 
(NM_002592.2 c.683G>T) PCNA variant in a wild-type control, and homozygous 
affected individual. (C-J) The clinical features of individuals homozygous for PCNA 
c.683G>T. Individual VI:6 aged 8 years (C) and 31 years (D) showing signs of 
premature aging. (E) Individual VI:7 aged 11 years with bilateral hearing aids insitu.  (F) 
Midline sagittal T1-weighted brain scan (individual VI:9 aged 8 years). There is atrophy 
of the cerebellar vermis resulting in enlargement of vermian sulci and mild widening of 
the fourth ventricle. The brainstem is normal in appearance and no supratentorial 
abnormality is shown. (G and H) Ocular and cutaneous telangiectasia (Individuals VI:7 
and VI:11).  (I) Pes Cavus (Individual VI:11). (J) Photosensitivity after minimal sun 
exposure (individual VI:11). 
  





Figure 2: Cells homozygous for PCNA p.Ser228Ile have normal replication 
parameters. (A) FACS analysis of S phase in primary cells. Cells (passage number 
<10) were labelled with BrdU for 30 minutes and BrdU incorporation and DNA content 
analyzed by FACS. No significant differences were observed between cells from 
affected individuals (P1, P3) and related (Het1) or unrelated (WT) control cells. 
Representative scatter plots are shown, each line was independently analyzed at least 
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twice. (B) Immunofluorescence of primary control cells (WT), Cockayne syndrome cells 
(CS) and affected individuals homozygous for PCNA p.Ser228Ile (P2 and P3). Soluble 
proteins were removed by triton extraction prior to fixation, and cells were 
immunostained for PCNA (right hand panels). The center panel shows sites of active 
DNA replication, visible as foci of incorporation of EdU (5-ethynyl-2´-deoxyuridine). 
Enlargement shows colocalization between these signals. DNA was counterstained with 
DAPI (left hand panel). Scale bars = 3μm. (C) Analysis of replication fork progression. 
Primary control cells and Cockayne syndrome cells (WT and CS) and cells homozygous 
for PCNA p.Ser228Ile (P2 and P3) were incubated sequentially in medium 
supplemented with IdU (5-iodo-2’-deoxyuridine) and CldU (5-chloro-2’-deoxyuridine), 
and the length of the DNA fiber replicated during each pulse measured. Comparable 
lengths of DNA were replicated during each pulse (top panel, compare light grey [IdU] 
and dark grey [CldU] bars for each cell line). The frequency distribution of the ratio of 
IdU/CldU within each fiber was similar between cell lines (bottom panel). The error bars 
indicate SEM of two experiments. 
 




Figure 3: Abnormal cellular responses to UV. (A) Primary fibroblasts from an 
affected individual are sensitive to UV. Cell survival was measured by colony-forming 
ability following exposure to the indicated doses of UVC. Plotted is the mean and range 
of two experiments. (B) Lymphoblastoid cells from two different affected individuals are 
sensitive to UV. Viable cells were counted 72 hours after exposure to UVC using trypan 
blue exclusion. Mean of three experiments +/- SEM. (C) Cells from affected individuals 
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have reduced UDS activity. Unscheduled DNA synthesis measured by incorporation of 
radiolabelled thymidine immediately after UV-irradiation of non-dividing cells with the 
indicated doses of UVC. Means + SEM of three experiments are shown. (D) RNA 
synthesis measured by the incorporation of radiolabelled uridine 24 h after UVC-
irradiation of non-dividing cells with indicated doses. Mean + SEM of three experiments. 
The reference line in grey shows a typical response of cells from a CS patient. (E) 
Defective RNA synthesis recovery is complemented by lentiviral transduction of primary 
patient fibroblasts with wild-type PCNA. RRS was measured using EdU incorporation 
and automated high content microscopy in cells expressing high levels of ectopic 








Figure 4: Perturbed PCNA interactions resulting from the p.Ser228Ile mutation. 
(A) Front and side views of the PCNA homotrimer, with Ser228 highlighted in 
magenta and the IDCL highlighted in cyan. Generated using POLYVIEW-3D (40), 
based on the 1YM crystal structure, rendered using PyMol. (B) Graphical representation 
of SILAC-based comparative PCNA-interaction analyses. Lysine [13C6/
15N2] and 
arginine [13C6/
15N4] labeled (H), or unlabeled (L), cell extracts were purified on wild type 
(WT) PCNA or p.Ser228Ile PCNA affinity columns and eluted proteins analyzed by 
mass spectrometry. Each point represents the observed H:L ratios of  a protein present 
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in 3/3 experiments. In blue are known PCNA interacting proteins (Table S1).  Proteins of 
particular interest are labeled by name. (C) Recombinant HisPCNA (WT or p.Ser228Ile) 
was added to HeLa cell extracts and proteins bound to nickel-NTA. Proteins eluted at 
1M NaCl or retained on the beads were analyzed by western blot for Fen1. (D) . Anti-
Fen1 immunoprecipitates, from extracts made from lymphoblastoid lines derived from 
affected individuals or family members, were analyzed by western blot for the presence 
of PCNA, Fen1, and actin. PCNA is almost undetectable in the precipitation from cell 
extracts derived from affected individuals. (E) E. coli lysates expressing empty vector 
(EV) or PCNA (WT or p.Ser228Ile) were mixed with lysates expressing GST or GST 
fused to the PIP box of Fen1. Inputs and glutathione-purified proteins were analyzed by 
SDS-PAGE and Coomassie staining.  (F) A similar experiment to E, except GST fusions 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
N
/K
 

 
N
/K
 
N
/K
 
+
+
 
+
+
 
A
ls
o
 h
y
p
o
m
y
e
li
n
a
ti
o
n
, 
P
u
ta
m
in
a
l 
c
a
lc
if
ic
a
ti
o
n
s
 
+
+
 
 
H
e
a
ri
n
g
 l
o
s
s
 

 
P
re
lin
g
u
a
l 

 
P
re
lin
g
u
a
l 

 
P
re
lin
g
u
a
l 

§
 
P
re
lin
g
u
a
l 
- 
+
+
 
P
ro
g
re
s
s
iv
e
, 
p
o
s
tl
in
g
u
a
l 
+
+
 
P
ro
g
re
s
s
iv
e
, 
p
o
s
tl
in
g
u
a
l 
A
D
D
IT
IO
N
A
L
 
F
E
A
T
U
R
E
S
 
 
 
 
 
 
 
 
 
P
re
m
a
tu
re
 a
g
in
g
 
 
N
/K
 
N
/K
 
- 

 
+
 
+
+
 
+
+
 
O
th
e
r 
p
h
y
s
ic
a
l 
fi
n
d
in
g
s
 
- 
- 
A
b
s
e
n
t 
p
u
b
e
rt
a
l 
g
ro
w
th
 s
p
u
rt
 
D
ia
p
h
ra
g
m
a
ti
c
 
h
e
rn
ia
, 
A
b
s
e
n
t 
p
u
b
e
rt
a
l 
g
ro
w
th
 s
p
u
rt
 
In
c
re
a
s
e
d
 r
is
k
 o
f 
le
u
k
e
m
ia
 
a
n
d
 l
y
m
p
h
o
m
a
 
In
c
o
m
p
le
te
 p
u
b
e
rt
y
, 
D
e
n
ta
l 
c
a
ri
e
s
 
 
